The key molecular events which lead to the development of premalignant oral lesions and their progression to oral cancer are still poorly understood. Much of the published research in this area has used well-defined cell culture models grown in monolayer which does not result in a physiological representation of the in vivo situation. In order to model this, tissue engineered mucosal constructs are a very useful tool, not only in allowing differentiation, but also in defining key events at the initiation of invasion. Identification of these key events may allow for the development of new diagnostics or therapeutic targets in early oral cancer, which would be very useful in reducing the continued poor survival seen in patients with this disease.
This project aims to address the following questions:
1. What are the differences/changes in the epigenome (methylation and miRNA expression) in TE models of dysplastic oral mucosa of varying grades, and also in those cells lines which invade?
This will be addressed using a panel of well-characterised oral dysplasia and SCC cell lines in our TE mucosal model system. The patterns of miRNA expression and methylation will be assessed in these tissues by TLDA array and methylation Arrays, using constructs derived from cells with varying grade of dysplasia and early invasion into the underlying matrix. The results will be validated using standard PCR/Methylation specific PCR.
2. Does the phenotype of the fibroblast used to construct the model affect the epigenome of the TE mucosal models?
It is now well established that control of epithelial function occurs form a number of stromal cells, including fibroblasts. We will construct the TS mucosal models with varying fibroblast phenotype, including normal, those derived from dysplastic tissue and tumour associated fibroblasts. Assays will be similar to above.
3. Which epigenetically controlled molecular pathways are being altered as dysplasia progresses and invasion is initiated? What is their function in the cells?
Candidate biomarkers identified will be functionally analysed, initially in monolayer culture, and if promising, in TE mucosa after stable alteration of expression. This will allow for assessment of the effects on functions such as proliferation, migration, invasion, apoptosis and other pro-tumourigenic capabilities.
4. Can these changes be seen in a cohort of tissues form patients with oral dysplasia and early invasive SCC?
We have access to a wide range of oral biopsy tissues to validate the findings in a clinical context and to assess their potential utility as biomarkers. This will be done in tissues by immunohistochemistry or in situ hybridisation, as appropriate.
Interested candidates should in the first instance contact (Professor Keith Hunter [email protected]
How to apply:
Please complete a University Postgraduate Research Application form available here: http://www.shef.ac.uk/postgraduate/research/apply
Please clearly state the prospective main supervisor in the respective box and select School of Clinical Dentistry as the department.